Methylene Blue: Preparations, Benefits, Doses and Safety

Methylene blue was made in a German dye works in 1876, to colour cotton. Within a few years Paul Ehrlich was using it to stain nerve tissue and bacteria under the microscope, and in 1891 he gave it to two patients with malaria, both of whom recovered. That made it the first fully synthetic compound ever used as a medicine. It went on to become the starting point for the phenothiazine chemistry that produced the first antipsychotic drugs, and it has never left the pharmacy.

It is also now sold as a mitochondrial supplement, in drops, capsules and troches, with claims ranging from sharper memory to slower ageing. Some of that has real human evidence behind it, some has animal evidence, and some has none. And unlike most supplements, methylene blue is a drug with a pharmacology that can genuinely hurt people who take it alongside the wrong medication.

What it does in the body

Methylene blue is a redox cycler. It accepts electrons, becoming colourless leucomethylene blue, and gives them up again, returning to blue. Almost everything it does follows from that.

It reverses methaemoglobinaemia. When the iron in haemoglobin is oxidised it can no longer carry oxygen. Reduced methylene blue hands electrons back, converting methaemoglobin to working haemoglobin within an hour. This is its approved indication, given intravenously at 1–2 mg/kg, and it is not in dispute.

It can carry electrons inside mitochondria. At low concentrations it takes electrons from NADH and passes them on to cytochrome c, bypassing complexes I and III of the electron transport chain. Where those complexes are impaired, that keeps oxygen consumption and ATP production going, and in several models it reduces the leakage of electrons that forms reactive oxygen species. This is the mechanism behind almost every cognitive, neuroprotective and anti-ageing claim, and it is real — mostly measured in cells and animals.

It inhibits monoamine oxidase A. Methylene blue is a potent inhibitor of MAO-A, the enzyme that breaks down serotonin. That is the source of both a possible mood effect and the one interaction that makes it dangerous, covered below.

The dose curve is not linear. Methylene blue is a textbook hormetic compound. At low doses it donates electrons and acts as an antioxidant; at high doses it pulls electrons away, becomes a pro-oxidant, and can itself cause the methaemoglobinaemia it treats at lower doses. The research range for its beneficial effects is roughly 0.5–4 mg/kg. Above about 5–7 mg/kg the side effects rise sharply. More is not better.

Taken by mouth, around 70 per cent is absorbed, it crosses the blood–brain barrier readily, and it is excreted largely in urine, which turns blue-green.

What the human evidence supports

Ranked from strongest to weakest.

Established

Methaemoglobinaemia. Approved, effective and fast
Surgical and diagnostic dye. Used to map sentinel lymph nodes, find parathyroid glands and trace fistulas and leaks
Ifosfamide encephalopathy. A confusional state caused by a chemotherapy drug, where methylene blue is used on the strength of case series and long clinical practice

Promising, from randomised trials

Malaria transmission. In trials in Mali and Burkina Faso, adding methylene blue to standard malaria treatment rapidly cleared gametocytes — the stage mosquitoes pick up — and sharply reduced infectivity to mosquitoes. It is one of the few compounds that block transmission this way. Blue urine is the main obstacle to wider use, not efficacy
Septic and vasoplegic shock. Methylene blue counters the nitric oxide surge that collapses blood pressure in septic shock and after cardiac surgery. A 2023 randomised trial in septic shock found faster weaning from vasopressors and shorter intensive care stays. This is hospital medicine, but it is a good illustration of a cheap, old drug being properly tested
Memory and brain activation. In a randomised, placebo-controlled study, a single oral dose of 280 mg increased functional MRI activity during memory and attention tasks in healthy adults, with a modest improvement in memory retrieval. One dose, one small study, and a clean result
Bipolar depression. In a randomised crossover trial, 195 mg a day added to lamotrigine reduced residual depression and anxiety compared with a 15 mg control dose. Small, but a proper design, and consistent with its MAO-A activity

Contested

Alzheimer's disease. A stabilised derivative, hydromethylthioninium, went through large phase 3 trials as an inhibitor of tau aggregation. The trials did not meet their primary endpoints as designed. The developer's favourable results came from later and subgroup analyses that remain disputed. The honest summary is: not shown to work, not clearly shown not to

Preclinical only

Ageing. Methylene blue delays senescence in cultured human fibroblasts and improves markers of skin ageing in skin models. Interesting, and entirely laboratory work
Neuroprotection. Protective in animal models of stroke, Parkinson's disease and traumatic brain injury. None of that has become a human result yet
Cancer. Used with light in photodynamic research. There is no evidence for oral methylene blue as a cancer treatment, and it should never delay or replace oncological care
Infections. Methylene blue plus light inactivates pathogens, which is how some European blood services treat donated plasma and how some dentists treat gum pockets. Swallowing it is a different situation; it is not an established oral antimicrobial, and it is not a treatment for intestinal parasites — for those, see the Parasite Protocol

The preparations, and how they differ

This is where most of the practical risk sits. The molecule is the same in every bottle. What else is in the bottle is not.

Preparation	Typical form	Who it is for	What to know
Pharmaceutical injection	5 mg/mL or 1% solution for intravenous use	Hospital treatment of methaemoglobinaemia, surgery, shock	The purest form, made to strict impurity limits. Not a home product
USP-grade powder	Powder meeting the United States Pharmacopeia monograph	Compounding pharmacies; the reference standard for oral use	USP grade sets limits for arsenic, lead and other heavy metals. This is the grade to look for on any oral product
Oral solution (drops)	Usually 1% (10 mg/mL) in water, sometimes weaker	Low-dose supplement use	Easy to dose by the drop, and messy: stains tongue, teeth and anything it touches. Check the grade and the concentration — products differ by a factor of ten
Capsules and tablets	Fixed doses, often 5–25 mg in supplements	Supplement use	No staining and precise dosing. Coating quality affects how much stomach irritation it causes
Troches and lozenges	Dissolved in the mouth	Supplement use	Partly absorbed through the mouth lining; stains the most
Combination urinary tablets	Methylene blue with methenamine and other agents	Prescription urinary antiseptic and symptom relief	A small dose of methylene blue in a medicine for urinary symptoms. The MAO-A interaction still applies
Hydromethylthioninium	Stabilised reduced form	Clinical trials in Alzheimer's disease	Investigational. Not a supplement
Industrial, laboratory and aquarium grades	Dye powder and fish-tank treatments	Staining, textiles, aquariums	Not made for human consumption and may carry heavy metals. Never swallow these

Choosing an oral product

USP grade, stated on the label, with a certificate of analysis for heavy metals from an independent laboratory
A clearly stated concentration or dose per unit, so that milligrams can actually be counted
A capsule if you want to avoid a blue mouth; drops if you want to adjust in small steps
Wariness of phrases like "pharmaceutical grade" without a USP statement — the phrase itself is not regulated

Doses, as they appear in the research

Human studies use doses by body weight, and the useful range is narrow at both ends.

0.5–4 mg/kg: the range in which the mitochondrial and cognitive effects appear in research
1–2 mg/kg intravenously: methaemoglobinaemia treatment
280 mg once: the functional MRI memory study, around 4 mg/kg for most participants
195 mg daily: the bipolar depression trial
Above about 5–7 mg/kg: where the risk of haemolysis, methaemoglobinaemia and confusion rises

The low milligram doses in most supplements — often 5 to 25 mg, a fraction of a milligram per kilogram — sit below every dose tested in the trials above. They have not been studied as such. That is not proof they do nothing; it means any effect at those doses is extrapolation.

Safety: read this before taking any

The serotonin interaction

This is the one that matters. Because methylene blue inhibits MAO-A, combining it with drugs that raise serotonin can cause serotonin toxicity: agitation, fever, rigid muscles, rapid heart rate, and in severe cases death. Regulators issued warnings after a series of cases, mostly in patients on antidepressants who received intravenous methylene blue during surgery.

Do not take methylene blue with:

SSRI and SNRI antidepressants, such as fluoxetine, sertraline, citalopram, escitalopram, paroxetine, venlafaxine and duloxetine
Clomipramine and other tricyclic antidepressants with serotonin activity
MAO inhibitors, including linezolid
Tramadol, pethidine, fentanyl and methadone
Dextromethorphan, found in many cough medicines
Triptans, buspirone, lithium, St John's wort, 5-HTP and tryptophan supplements

Fluoxetine stays in the body for weeks after the last dose, so stopping it the day before is not enough. Anyone on a serotonergic medication should not start methylene blue without the prescriber involved.

Who should not take it

G6PD deficiency. Methylene blue can cause severe haemolysis, and in this condition it also fails to treat methaemoglobinaemia. G6PD deficiency is common in people with African, Mediterranean, Middle Eastern and Asian ancestry, and many carriers do not know. A blood test settles it
Pregnancy and breastfeeding. It has caused fetal harm
Significant kidney impairment, because it is cleared through the kidneys
Children, outside medical treatment

Other effects to expect or watch

Blue-green urine, and sometimes blue stools and a blue tongue. Harmless and expected
Nausea and stomach upset, less with food
Increased sensitivity to sunlight
A falsely low pulse oximeter reading, because the dye absorbs the same light the device uses. Worth telling anyone who measures your oxygen
Headache or dizziness at higher doses

The summary

Methylene blue is not a fringe compound. It is an essential medicine with a hundred and fifty years of history, a well-understood mechanism, and a small but real body of randomised human evidence — for memory and brain activity after a single dose, for residual bipolar depression, for blocking malaria transmission and for septic shock. Its mitochondrial and anti-ageing reputation rests mostly on laboratory and animal work, and should be described that way.

The case for respecting it is as strong as the case for its benefits. The dose curve turns over, the useful range is narrow, the supplement doses mostly sit below anything tested, and the serotonin interaction is severe enough that it must be checked before the first dose rather than after the first symptom. Used with USP-grade product, at a dose someone has actually counted, by someone not on serotonergic medication and without G6PD deficiency, it is a reasonable thing to try. Without those conditions, it is not.

Educational information, not medical advice. Anyone taking antidepressants or other serotonergic medication, pregnant or breastfeeding, or with kidney disease or possible G6PD deficiency should speak to a doctor before taking methylene blue.